UAB „AstraZeneca Lietuva“


Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.



We want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. Our ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them.



We are leading a revolution in oncology to redefine cancer care. We have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.

Our purpose and values

Our purpose and values help explain why we exist, what we hope to accomplish, the behaviours we value, how we will achieve our goals, and the promise of our brand to our stakeholders.

We push the boundaries of science to deliver life-changing medicines.

Our purpose underpins everything we do. It gives us a reason to come to work every day. It reminds us why we exist as a company. It helps us deliver benefits to patients and create value for shareholders. It also sets the context for our employees’ activities and the roles of our teams, partners and other collaborators.

We follow the science. We put patients first. We play to win. We do the right thing. We are entrepreneurial.

Our values determine how we work together and the behaviours that are integral to our drive for success. Our values guide our decision making, define our beliefs and foster a strong AstraZeneca culture.

The path to new treatments

The future of treatment for many of today’s diseases lies in uncovering mechanisms that are newly emerging or are still to be discovered. We believe the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them. Our focus is on the following: Cardiovascular, Renal and Metabolism; Oncology; Respiratory, Inflammation and Autoimmunity; Infection and Vaccines; and Neuroscience.


Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer.

Cardiovascular, Renal and Metabolism

CVRM (Cardiovascular, Renal and Metabolism) is one of our main therapy areas because science continues to uncover commonalities between metabolism, heart failure, arterial vascular disease and renal disease – four distinct but interrelated areas.

Entering a new era in vascular and cardiac regeneration research
As we move novel therapeutic modalities from the laboratory into clinical trials, we are focusing on the repair and regeneration of tissues with the potential to treat life threatening cardiovascular diseases such as heart failure.

Respiratory & Immunology

We are entering an era of unprecedented potential to deliver scientific breakthroughs within asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and chronic cough.

Other disease areas

We have medicines and vaccines in other disease areas that have an important impact for patients. As such, we are selectively active in the areas of autoimmunity, infection & vaccines, neuroscience and gastroenterology, where we follow an opportunity-driven approach and often work through partnerships.


Spaudos g. 6-1, LT-05132, Vilnius, Lietuva
+370 52660550
Fax:+370 52660555